Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07340593Completed

Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study

Role: collaborator

NCT07211880Not ApplicableCompleted

Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study

Role: collaborator

NCT01514019Phase 4Completed

An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers

Role: collaborator

NCT00735228Not ApplicableUnknown

Tight Glycemic Control by Artificial Pancreas

Role: collaborator

NCT00281047Phase 2Unknown

The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

Role: collaborator

All 5 trials loaded